Physician profile
Parag Jain
NPI 1396790911
$8,055.49
in general payments reported to CMS, 2019-2025
33 companies · $2,075 in 2025
The $2,075 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $813 · 2020: $258 · 2021: $863 · 2022: $522 · 2023: $2,653 · 2024: $872 · 2025: $2,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,200 · Honoraria: $1,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,199.51 |
| Honoraria | $1,400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Altathera Pharmaceuticals LLC | $1,400.00 | 2023 | Sotalol Hydrochloride |
| Novartis Pharmaceuticals Corporation | $702.47 | 2019-2025 | |
| Aop Health US, LLC | $696.77 | 2025 | Rapiblyk |
| Pfizer INC. | $671.98 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $662.82 | 2019-2025 | Wainua, Farxiga, Lokelma |
| E.R. Squibb & Sons, L.L.C. | $510.17 | 2019-2025 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $488.67 | 2019-2025 | Lifevest |
| Novo Nordisk INC | $307.23 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $294.42 | 2021-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $289.78 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $268.30 | 2019-2023 | Xarelto |
| Boston Scientific Corporation | $261.87 | 2022-2025 | General - Therapies, Lux-Dx Insertable Cardiac Monitor, Watchman Access System |
| Regeneron Healthcare Solutions, INC. | $188.40 | 2019-2025 | Evkeeza, Praluent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.79 | 2022-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $140.33 | 2021-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $139.34 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $126.62 | 2021-2025 | Amvuttra |
| Esperion Therapeutics, INC. | $93.36 | 2021 | |
| Kestra Medical Technology Services, INC. | $90.68 | 2025 | Assure Wcd |
| Lexicon Pharmaceuticals, INC. | $82.27 | 2023-2024 | Inpefa |
| Abbott Laboratories | $69.51 | 2023-2025 | Cardiomems |
| Scpharmaceuticals INC. | $66.98 | 2023-2025 | |
| Amgen INC. | $64.26 | 2019-2025 | Repatha |
| Lundbeck LLC | $58.09 | 2019 | |
| Inspire Medical Systems, INC. | $58.03 | 2023 | Inspire |
| Chiesi USA, INC. | $38.89 | 2024-2025 | Juxtapid |
| Abbvie INC. | $28.09 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $27.45 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $26.48 | 2024 | Arcalyst |
| Currax Pharmaceuticals LLC | $14.31 | 2025 | Onzetra Xsail, Contrave |
| Azurity Pharmaceuticals, INC. | $14.29 | 2023 | Edarbi |
| Arbor Pharmaceuticals, INC. | $14.07 | 2020 | |
| Lilly USA, LLC | $13.77 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parag Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.